Ourania Tatsis - Feb 17, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Reg. & Quality Off.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 17, 2023
Transactions value $
-$1,458,241
Form type
4
Date filed
2/22/2023, 03:48 PM
Previous filing
Feb 16, 2023
Next filing
Feb 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$1.32M -4.5K -6.87% $292.85 60.9K Feb 17, 2023 Direct
transaction VRTX Common Stock Sale -$1.16K -4 -0.01% $291.01 60.9K Feb 21, 2023 Direct F1
transaction VRTX Common Stock Sale -$42.5K -145 -0.24% $292.85 60.8K Feb 21, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$60.8K -207 -0.34% $293.83 60.6K Feb 21, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$36.6K -124 -0.2% $294.77 60.5K Feb 21, 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36).
F4 Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38).
F5 Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37).